Tue Sep 10 18:53:00 UTC 2024: ## Rosen Law Firm Files Class Action Lawsuit Against Sage Therapeutics

**NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE)** – The Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit against Sage Therapeutics, Inc. (NASDAQ: SAGE) on behalf of investors who purchased Sage securities between April 12, 2021 and July 23, 2024.

The lawsuit alleges that Sage made misleading statements about the efficacy of its drug candidates, including zuranolone for postpartum depression and major depressive disorder, SAGE-718 for mild cognitive impairment, and SAGE-324 for essential tremor. The firm claims that Sage overstated the effectiveness of these drugs and their regulatory and commercial prospects, leading to inflated stock prices.

Investors who purchased Sage securities during the class period may be eligible for compensation. The deadline to move the court to serve as lead plaintiff is October 28, 2024. Interested individuals can find more information and join the class action by visiting https://rosenlegal.com/submit-form/?case_id=28360 or contacting Phillip Kim, Esq. at 866-767-3653 or case@rosenlegal.com.

The Rosen Law Firm is known for its expertise in securities class actions and shareholder derivative litigation, having achieved the largest ever securities class action settlement against a Chinese Company. The firm has a proven track record of success and has recovered hundreds of millions of dollars for investors.

**About The Rosen Law Firm:**

The Rosen Law Firm represents investors globally, focusing on securities class actions and shareholder derivative litigation. The firm has a strong reputation for its commitment to client advocacy and its success in securing favorable outcomes for investors.

Read More